KR101773208B1 - 질소 함유 스피로 고리 화합물 및 이의 의약 용도 - Google Patents

질소 함유 스피로 고리 화합물 및 이의 의약 용도 Download PDF

Info

Publication number
KR101773208B1
KR101773208B1 KR1020127001455A KR20127001455A KR101773208B1 KR 101773208 B1 KR101773208 B1 KR 101773208B1 KR 1020127001455 A KR1020127001455 A KR 1020127001455A KR 20127001455 A KR20127001455 A KR 20127001455A KR 101773208 B1 KR101773208 B1 KR 101773208B1
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
solvate
acceptable salt
compound according
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127001455A
Other languages
English (en)
Korean (ko)
Other versions
KR20120051649A (ko
Inventor
사토루 노지
마코토 시오자키
도모야 미우라
요시노리 하라
히로시 야마나카
가츠야 마에다
아키미 호리
마사후미 이노우에
야스노리 하세
Original Assignee
니뽄 다바코 산교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101773208(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 니뽄 다바코 산교 가부시키가이샤 filed Critical 니뽄 다바코 산교 가부시키가이샤
Publication of KR20120051649A publication Critical patent/KR20120051649A/ko
Application granted granted Critical
Publication of KR101773208B1 publication Critical patent/KR101773208B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020127001455A 2009-07-31 2010-07-30 질소 함유 스피로 고리 화합물 및 이의 의약 용도 Active KR101773208B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009179502 2009-07-31
JPJP-P-2009-179502 2009-07-31
US27413709P 2009-08-13 2009-08-13
US61/274,137 2009-08-13
PCT/JP2010/062873 WO2011013785A1 (ja) 2009-07-31 2010-07-30 含窒素スピロ環化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
KR20120051649A KR20120051649A (ko) 2012-05-22
KR101773208B1 true KR101773208B1 (ko) 2017-08-31

Family

ID=43529436

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127001455A Active KR101773208B1 (ko) 2009-07-31 2010-07-30 질소 함유 스피로 고리 화합물 및 이의 의약 용도

Country Status (36)

Country Link
US (4) US8609647B2 (enExample)
EP (3) EP3181570A1 (enExample)
JP (9) JP5520158B2 (enExample)
KR (1) KR101773208B1 (enExample)
CN (1) CN102510865B (enExample)
AR (1) AR077497A1 (enExample)
AU (1) AU2010278066B2 (enExample)
BR (1) BR112012002157B1 (enExample)
CA (1) CA2767899C (enExample)
CO (1) CO6491052A2 (enExample)
CY (1) CY1118747T1 (enExample)
DK (1) DK2460806T3 (enExample)
ES (1) ES2616705T3 (enExample)
FI (1) FIC20250012I1 (enExample)
FR (1) FR25C1010I1 (enExample)
HR (1) HRP20170447T1 (enExample)
HU (2) HUE033070T2 (enExample)
IL (1) IL217048A (enExample)
LT (2) LT2460806T (enExample)
ME (1) ME02667B (enExample)
MX (1) MX2012001313A (enExample)
MY (1) MY163495A (enExample)
NL (1) NL301321I2 (enExample)
NO (1) NO2025014I1 (enExample)
NZ (1) NZ597994A (enExample)
PE (1) PE20121276A1 (enExample)
PL (1) PL2460806T3 (enExample)
PT (1) PT2460806T (enExample)
RS (1) RS55913B1 (enExample)
RU (1) RU2630694C2 (enExample)
SG (1) SG176918A1 (enExample)
SI (1) SI2460806T1 (enExample)
SM (1) SMT201700166T1 (enExample)
TW (1) TWI466885B (enExample)
WO (1) WO2011013785A1 (enExample)
ZA (1) ZA201200689B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
BR112013003864B1 (pt) * 2010-08-20 2021-08-31 Hutchison Medipharma Limited Compostos de pirrolpirimidina, composição e uso dos mesmos
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
ES2682755T3 (es) 2011-12-21 2018-09-21 Jiangsu Hengrui Medicine Co. Ltd. Derivado del anillo heteroarilo de seis miembros de pirrol, método de preparación del mismo y sus usos medicinales
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
US20160367556A1 (en) * 2013-10-21 2016-12-22 Japan Tobacco Inc. Therapeutic Agent for Ocular Disease or Prophylactic Agent for Ocular Disease
CN106661033B (zh) * 2014-05-28 2018-11-06 阿斯利康(瑞典)有限公司 用于制备azd5363的方法和在其中使用的新颖中间体
HK1251223A1 (en) * 2015-07-07 2019-01-25 Japan Tobacco, Inc. Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
PL3352734T3 (pl) * 2015-09-24 2020-08-24 Leo Pharma A/S Leczenie łysienia plackowatego
PT3353168T (pt) * 2015-09-25 2023-09-20 Dizal Jiangsu Pharmaceutical Co Ltd Compostos e métodos para inibir jak
IL313543A (en) 2016-01-21 2024-08-01 Leo Pharma As Treatment of hand eczema
KR102538803B1 (ko) 2016-08-01 2023-06-01 앱티닉스 인크. 스피로-락탐 nmda 조정제 및 그의 사용 방법
JP6937828B2 (ja) * 2016-11-23 2021-09-22 江蘇恒瑞医薬股▲ふん▼有限公司 ピロロ６員複素芳香環誘導体の製造方法、および中間体
CA3047891A1 (en) * 2016-12-21 2018-06-28 Japan Tobacco Inc. Process for preparing 7h-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof
WO2018117153A1 (en) * 2016-12-21 2018-06-28 Japan Tobacco Inc. Crystalline forms of a janus kinase inhibitor
BR112019012267A2 (pt) * 2016-12-21 2019-12-03 Japan Tobacco Inc processo para a preparação do derivado de 7h-pirrolo [2,3-d]pirimidina e cocristais do mesmo
RU2764980C2 (ru) * 2017-01-20 2022-01-24 Лео Фарма А/С Бициклические амины в качестве новых ингибиторов jak-киназы
US10799507B2 (en) * 2017-02-03 2020-10-13 Leo Pharma A/S 5-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2.5]octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors
WO2019075073A2 (en) * 2017-10-10 2019-04-18 Biogen Inc. PROCESS FOR THE PREPARATION OF SPIRO DERIVATIVES
SG11202007251XA (en) * 2018-01-31 2020-08-28 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2020007698A1 (en) * 2018-07-06 2020-01-09 Leo Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
AU2020275208B2 (en) 2019-05-15 2025-12-04 Leo Pharma A/S Formulation of delgocitinib in the form of a cream
CN118903144A (zh) * 2019-08-07 2024-11-08 乐敦制药株式会社 泪液分泌促进用眼科组合物
CN119367282A (zh) * 2019-12-27 2025-01-28 乐敦制药株式会社 水性组合物
CN111574540B (zh) * 2020-06-30 2023-08-29 云南华派医药科技有限公司 一种德高替尼的制备方法
CN111560021B (zh) * 2020-06-30 2023-05-26 上海鲲博玖瑞医药科技发展有限公司 一种德高替尼中间体及其制备方法
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
CN114591321A (zh) * 2020-12-04 2022-06-07 广州费米子科技有限责任公司 氮杂并环化合物、其制备方法及其用途
WO2022143629A1 (zh) * 2020-12-29 2022-07-07 上海岸阔医药科技有限公司 治疗与抗肿瘤剂相关的皮肤疾病或病症的试剂和方法
JP2025514747A (ja) 2022-04-20 2025-05-09 レオ ファーマ アクティーゼルスカブ 前頭部線維性脱毛症の治療
WO2024180493A1 (en) 2023-02-28 2024-09-06 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
KR20250159260A (ko) 2023-03-17 2025-11-10 레오 파마 에이/에스 중등도 내지 중증의 만성 손 습진 환자의 만성 손 습진 치료 방법
WO2024225445A1 (en) 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib
WO2025085050A1 (en) * 2023-10-16 2025-04-24 Leo Pharma A/S Treatment of frontal fibrosing alopecia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065909A1 (en) 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006127587A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2008119792A1 (en) 2007-04-02 2008-10-09 Palau Pharma, S. A. Pyrrolopyrimidine derivatives as jak3 inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL204628B1 (pl) 1998-06-02 2010-01-29 Osi Pharmaceuticals Pochodna pirolo[2,3d]pirymidyny, jej zastosowanie i sposoby wytwarzania tej pochodnej i preparaty farmaceutyczne
EP1087970B1 (en) * 1998-06-19 2004-04-28 Pfizer Products Inc. PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS
CN1195755C (zh) * 1999-12-10 2005-04-06 辉瑞产品公司 吡咯并[2,3－d]嘧啶化合物
EA009789B1 (ru) * 2002-07-05 2008-04-28 Таргасепт, Инк. N-арилдиазаспирациклические соединения и способы их получения и применения
EP1683797A1 (en) 2003-11-13 2006-07-26 Ono Pharmaceutical Co., Ltd. Heterocyclic spiro compound
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
EP1858902A1 (en) 2005-02-24 2007-11-28 Pfizer Products Incorporated Bicyclic heteroaromatic derivatives useful as anticancer agents
EP1910358A2 (en) * 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
PT1966202E (pt) 2005-12-13 2012-01-03 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2008029237A2 (en) 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis
WO2008077811A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
EP2209775A1 (en) * 2007-10-09 2010-07-28 UCB Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
TW200940542A (en) 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CL2009001152A1 (es) 2008-05-13 2009-10-16 Array Biopharma Inc Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
WO2010003133A2 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
JP2018028525A (ja) * 2016-08-15 2018-02-22 小野　信行 イオンレーザーと重水素を利用した核融合炉
JP6229778B2 (ja) * 2016-09-21 2017-11-15 サミー株式会社 遊技機

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999065909A1 (en) 1998-06-19 1999-12-23 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2006127587A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
WO2008119792A1 (en) 2007-04-02 2008-10-09 Palau Pharma, S. A. Pyrrolopyrimidine derivatives as jak3 inhibitors

Also Published As

Publication number Publication date
ME02667B (me) 2017-06-20
NO2025014I1 (no) 2025-03-04
AR077497A1 (es) 2011-08-31
TW201107325A (en) 2011-03-01
JP2016029104A (ja) 2016-03-03
CY1118747T1 (el) 2017-07-12
CA2767899A1 (en) 2011-02-03
JP2011046700A (ja) 2011-03-10
MX2012001313A (es) 2012-02-29
LTPA2025511I1 (enExample) 2025-03-25
SMT201700166T1 (it) 2017-05-08
AU2010278066A1 (en) 2012-03-01
EP2460806A1 (en) 2012-06-06
JP2020033384A (ja) 2020-03-05
PE20121276A1 (es) 2012-09-27
JP5520158B2 (ja) 2014-06-11
BR112012002157A2 (pt) 2020-08-18
HRP20170447T1 (hr) 2017-05-19
EP3858349A1 (en) 2021-08-04
JP2021183653A (ja) 2021-12-02
US20240150367A1 (en) 2024-05-09
IL217048A (en) 2014-12-31
ZA201200689B (en) 2012-10-31
EP2460806A4 (en) 2012-12-26
CN102510865A (zh) 2012-06-20
US20230023377A1 (en) 2023-01-26
NL301321I2 (nl) 2025-07-17
KR20120051649A (ko) 2012-05-22
HUE033070T2 (hu) 2017-11-28
IL217048A0 (en) 2012-02-29
EP2460806B1 (en) 2017-01-04
ES2616705T3 (es) 2017-06-14
HUS2500013I1 (hu) 2025-03-28
US20110136778A1 (en) 2011-06-09
PT2460806T (pt) 2017-02-27
CN102510865B (zh) 2015-04-15
RU2012106344A (ru) 2013-08-27
US20140187534A1 (en) 2014-07-03
MY163495A (en) 2017-09-15
RU2630694C2 (ru) 2017-09-12
RS55913B1 (sr) 2017-09-29
NZ597994A (en) 2013-08-30
TWI466885B (zh) 2015-01-01
AU2010278066B2 (en) 2016-04-14
EP3181570A1 (en) 2017-06-21
JP2025109780A (ja) 2025-07-25
CA2767899C (en) 2018-08-28
PL2460806T3 (pl) 2017-06-30
FIC20250012I1 (fi) 2025-02-28
JP2023138641A (ja) 2023-10-02
FR25C1010I1 (fr) 2025-04-25
US8609647B2 (en) 2013-12-17
SI2460806T1 (sl) 2017-04-26
LT2460806T (lt) 2017-02-10
JP2017019877A (ja) 2017-01-26
WO2011013785A1 (ja) 2011-02-03
JP2018111701A (ja) 2018-07-19
JP2014141516A (ja) 2014-08-07
BR112012002157B1 (pt) 2022-02-08
SG176918A1 (en) 2012-01-30
DK2460806T3 (en) 2017-03-20
CO6491052A2 (es) 2012-07-31

Similar Documents

Publication Publication Date Title
KR101773208B1 (ko) 질소 함유 스피로 고리 화합물 및 이의 의약 용도
AU2013290054A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
JPWO2008072655A1 (ja) イミダゾチアゾール誘導体
EP3844159B1 (en) Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease
WO2014003098A1 (ja) 三環性化合物
US10851116B2 (en) Bicyclic amines as novel JAK kinase inhibitors
JP2009298713A (ja) イミダゾチアゾール誘導体
TW202227459A (zh) 胺衍生物
HK1166499B (en) Nitrogen-containing spiro-ring compound and medicinal use of same
HK1166499A (en) Nitrogen-containing spiro-ring compound and medicinal use of same

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

S14 Exclusive voluntary license recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-S10-S14-LIC-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

S14-X000 Exclusive voluntary license recorded

St.27 status event code: A-4-4-S10-S14-lic-X000